The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease

B. R. Bloem; W. J. Marks; A. L. Silva de Lima; M. L. Kuijf; T. van Laar; B. P. F. Jacobs; M. M. Verbeek; R. C. Helmich; B. P. van de Warrenburg; L. J. W. Evers; J. IntHout; T. van de Zande; T. M. Snyder; R. Kapur; M. J. Meinders

doi:10.1186/s12883-019-1394-3

The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease

B. R. Bloem^*, W. J. Marks, A. L. Silva de Lima, M. L. Kuijf, T. van Laar, B. P. F. Jacobs, M. M. Verbeek, R. C. Helmich, B. P. van de Warrenburg, L. J. W. Evers, J. IntHout, T. van de Zande, T. M. Snyder, R. Kapur, M. J. Meinders

^*Corresponding author for this work

Biology-Related, Artificial, and Interventional Neuroscience (BRAIN)

Research output: Contribution to journal › Article › Academic › peer-review

75 Citations (Scopus)

380 Downloads (Pure)

Abstract

Background: Our understanding of the etiology, pathophysiology, phenotypic diversity, and progression of Parkinson's disease has stagnated. Consequently, patients do not receive the best care, leading to unnecessary disability, and to mounting costs for society. The Personalized Parkinson Project (PPP) proposes an unbiased approach to biomarker development with multiple biomarkers measured longitudinally. Our main aims are: (a) to perform a set of hypothesis-driven analyses on the comprehensive dataset, correlating established and novel biomarkers to the rate of disease progression and to treatment response; and (b) to create a widely accessible dataset for discovery of novel biomarkers and new targets for therapeutic interventions in Parkinson's disease.

Methods/design: This is a prospective, longitudinal, single-center cohort study. The cohort will comprise 650 persons with Parkinson's disease. The inclusion criteria are purposely broad: age >= 18 years; and disease duration

Discussion: The PPP has several distinguishing elements: all assessments are done in a single center; inclusion of "real life" subjects; deep and repeated multi-dimensional phenotyping; and continuous monitoring with a wearable device for 2 years. Also, the PPP is powered by privacy and security by design, allowing for data sharing with scientists worldwide respecting participants' privacy. The data are expected to open the way for important new insights, including identification of biomarkers to predict differences in prognosis and treatment response between patients. Our long-term aim is to improve existing treatments, develop new therapeutic approaches, and offer Parkinson's disease patients a more personalized disease management approach.

Original language	English
Article number	160
Number of pages	10
Journal	BMC NEUROLOGY
Volume	19
DOIs	https://doi.org/10.1186/s12883-019-1394-3
Publication status	Published - 17-Jul-2019

Keywords

Cohort studies
Parkinson's disease
Biomarkers
Disease progression
Wearable device
MILD COGNITIVE IMPAIRMENT
VALIDITY
QUESTIONNAIRE
RELIABILITY
SLEEPINESS
SUBTYPES
SCALES
CARE

Access to Document

10.1186/s12883-019-1394-3Licence: CC BY

The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s diseaseFinal publisher's version, 459 KBLicence: CC BY

Handle.net

Persistent link

Cite this

Bloem, B. R., Marks, W. J., Silva de Lima, A. L., Kuijf, M. L., van Laar, T., Jacobs, B. P. F., Verbeek, M. M., Helmich, R. C., van de Warrenburg, B. P., Evers, L. J. W., IntHout, J., van de Zande, T., Snyder, T. M., Kapur, R., & Meinders, M. J. (2019). The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease. BMC NEUROLOGY, 19, Article 160. https://doi.org/10.1186/s12883-019-1394-3

@article{d656a600630e4809bd1ee5f4dbf97e95,

title = "The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease",

abstract = "Background: Our understanding of the etiology, pathophysiology, phenotypic diversity, and progression of Parkinson's disease has stagnated. Consequently, patients do not receive the best care, leading to unnecessary disability, and to mounting costs for society. The Personalized Parkinson Project (PPP) proposes an unbiased approach to biomarker development with multiple biomarkers measured longitudinally. Our main aims are: (a) to perform a set of hypothesis-driven analyses on the comprehensive dataset, correlating established and novel biomarkers to the rate of disease progression and to treatment response; and (b) to create a widely accessible dataset for discovery of novel biomarkers and new targets for therapeutic interventions in Parkinson's disease.Methods/design: This is a prospective, longitudinal, single-center cohort study. The cohort will comprise 650 persons with Parkinson's disease. The inclusion criteria are purposely broad: age >= 18 years; and disease durationDiscussion: The PPP has several distinguishing elements: all assessments are done in a single center; inclusion of {"}real life{"} subjects; deep and repeated multi-dimensional phenotyping; and continuous monitoring with a wearable device for 2 years. Also, the PPP is powered by privacy and security by design, allowing for data sharing with scientists worldwide respecting participants' privacy. The data are expected to open the way for important new insights, including identification of biomarkers to predict differences in prognosis and treatment response between patients. Our long-term aim is to improve existing treatments, develop new therapeutic approaches, and offer Parkinson's disease patients a more personalized disease management approach.",

keywords = "Cohort studies, Parkinson's disease, Biomarkers, Disease progression, Wearable device, MILD COGNITIVE IMPAIRMENT, VALIDITY, QUESTIONNAIRE, RELIABILITY, SLEEPINESS, SUBTYPES, SCALES, CARE",

author = "Bloem, {B. R.} and Marks, {W. J.} and {Silva de Lima}, {A. L.} and Kuijf, {M. L.} and {van Laar}, T. and Jacobs, {B. P. F.} and Verbeek, {M. M.} and Helmich, {R. C.} and {van de Warrenburg}, {B. P.} and Evers, {L. J. W.} and J. IntHout and {van de Zande}, T. and Snyder, {T. M.} and R. Kapur and Meinders, {M. J.}",

year = "2019",

month = jul,

day = "17",

doi = "10.1186/s12883-019-1394-3",

language = "English",

volume = "19",

journal = "BMC NEUROLOGY",

issn = "1471-2377",

publisher = "BioMed Central Ltd.",

}

Bloem, BR, Marks, WJ, Silva de Lima, AL, Kuijf, ML, van Laar, T, Jacobs, BPF, Verbeek, MM, Helmich, RC, van de Warrenburg, BP, Evers, LJW, IntHout, J, van de Zande, T, Snyder, TM, Kapur, R & Meinders, MJ 2019, 'The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease', BMC NEUROLOGY, vol. 19, 160. https://doi.org/10.1186/s12883-019-1394-3

TY - JOUR

T1 - The Personalized Parkinson Project

T2 - examining disease progression through broad biomarkers in early Parkinson's disease

AU - Bloem, B. R.

AU - Marks, W. J.

AU - Silva de Lima, A. L.

AU - Kuijf, M. L.

AU - van Laar, T.

AU - Jacobs, B. P. F.

AU - Verbeek, M. M.

AU - Helmich, R. C.

AU - van de Warrenburg, B. P.

AU - Evers, L. J. W.

AU - IntHout, J.

AU - van de Zande, T.

AU - Snyder, T. M.

AU - Kapur, R.

AU - Meinders, M. J.

PY - 2019/7/17

Y1 - 2019/7/17

N2 - Background: Our understanding of the etiology, pathophysiology, phenotypic diversity, and progression of Parkinson's disease has stagnated. Consequently, patients do not receive the best care, leading to unnecessary disability, and to mounting costs for society. The Personalized Parkinson Project (PPP) proposes an unbiased approach to biomarker development with multiple biomarkers measured longitudinally. Our main aims are: (a) to perform a set of hypothesis-driven analyses on the comprehensive dataset, correlating established and novel biomarkers to the rate of disease progression and to treatment response; and (b) to create a widely accessible dataset for discovery of novel biomarkers and new targets for therapeutic interventions in Parkinson's disease.Methods/design: This is a prospective, longitudinal, single-center cohort study. The cohort will comprise 650 persons with Parkinson's disease. The inclusion criteria are purposely broad: age >= 18 years; and disease durationDiscussion: The PPP has several distinguishing elements: all assessments are done in a single center; inclusion of "real life" subjects; deep and repeated multi-dimensional phenotyping; and continuous monitoring with a wearable device for 2 years. Also, the PPP is powered by privacy and security by design, allowing for data sharing with scientists worldwide respecting participants' privacy. The data are expected to open the way for important new insights, including identification of biomarkers to predict differences in prognosis and treatment response between patients. Our long-term aim is to improve existing treatments, develop new therapeutic approaches, and offer Parkinson's disease patients a more personalized disease management approach.

AB - Background: Our understanding of the etiology, pathophysiology, phenotypic diversity, and progression of Parkinson's disease has stagnated. Consequently, patients do not receive the best care, leading to unnecessary disability, and to mounting costs for society. The Personalized Parkinson Project (PPP) proposes an unbiased approach to biomarker development with multiple biomarkers measured longitudinally. Our main aims are: (a) to perform a set of hypothesis-driven analyses on the comprehensive dataset, correlating established and novel biomarkers to the rate of disease progression and to treatment response; and (b) to create a widely accessible dataset for discovery of novel biomarkers and new targets for therapeutic interventions in Parkinson's disease.Methods/design: This is a prospective, longitudinal, single-center cohort study. The cohort will comprise 650 persons with Parkinson's disease. The inclusion criteria are purposely broad: age >= 18 years; and disease durationDiscussion: The PPP has several distinguishing elements: all assessments are done in a single center; inclusion of "real life" subjects; deep and repeated multi-dimensional phenotyping; and continuous monitoring with a wearable device for 2 years. Also, the PPP is powered by privacy and security by design, allowing for data sharing with scientists worldwide respecting participants' privacy. The data are expected to open the way for important new insights, including identification of biomarkers to predict differences in prognosis and treatment response between patients. Our long-term aim is to improve existing treatments, develop new therapeutic approaches, and offer Parkinson's disease patients a more personalized disease management approach.

KW - Cohort studies

KW - Parkinson's disease

KW - Biomarkers

KW - Disease progression

KW - Wearable device

KW - MILD COGNITIVE IMPAIRMENT

KW - VALIDITY

KW - QUESTIONNAIRE

KW - RELIABILITY

KW - SLEEPINESS

KW - SUBTYPES

KW - SCALES

KW - CARE

U2 - 10.1186/s12883-019-1394-3

DO - 10.1186/s12883-019-1394-3

M3 - Article

SN - 1471-2377

VL - 19

JO - BMC NEUROLOGY

JF - BMC NEUROLOGY

M1 - 160

ER -

The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this